Texas medical device companies developing cancer-related products can access significant funding through the Cancer Prevention and Research Institute of Texas (CPRIT). CPRIT's Product Development Research Awards fund the commercialization of cancer diagnostics, imaging devices, surgical tools, drug delivery systems, and other medical devices that address cancer prevention, detection, or treatment.
What CPRIT Funds for Medical Devices
CPRIT product development awards can fund a broad range of medical device activities:
- Diagnostic devices: Molecular diagnostics, point- of-care testing devices, imaging technologies, and liquid biopsy platforms for cancer detection
- Therapeutic devices: Surgical tools, radiation delivery systems, ablation devices, and implantable drug delivery systems for cancer treatment
- Enabling technologies: AI-powered imaging analysis, robotic surgery platforms, and specimen processing systems that support cancer care
- Regulatory and clinical activities: FDA submissions (510(k), PMA, De Novo), clinical trials, and manufacturing validation
Award Structure
- Award sizes: Product development awards typically range from $1 million to $20 million or more, depending on development stage and scope
- Non-dilutive: CPRIT awards are structured as contracts with revenue-sharing provisions, not equity investments
- Milestone-driven: Funding is disbursed against specific development milestones agreed upon in the contract
- Texas presence required: Principal operations must be in Texas during the award period
Eligibility Requirements
- The company must be a for-profit entity headquartered in Texas or willing to relocate principal operations to Texas
- The product must have a clear cancer application — prevention, detection, diagnosis, or treatment
- The company must demonstrate matching funds (ratio varies by development stage)
- The technology must have a clear path to regulatory approval and commercialization
Medical Device Regulatory Pathway
CPRIT reviewers evaluate the regulatory strategy as part of the application. Medical device companies should have a clear understanding of their FDA pathway:
- 510(k): For devices substantially equivalent to a legally marketed predicate device
- De Novo: For novel, low-to-moderate risk devices without a predicate
- PMA: For Class III devices requiring clinical evidence of safety and effectiveness
- Breakthrough Device designation: For devices that address life-threatening conditions — provides faster FDA review and intensive interaction
Complementary Programs
- SBIR/STTR (NIH): Federal grants for early-stage medical device R&D. SBIR/NIH guide.
- R&D tax credits: Medical device R&D expenses qualify for federal tax credits. R&D credits guide.
- CPRIT biotech programs: CPRIT for biotech startups guide.
Bottom Line
CPRIT provides some of the largest non-dilutive funding awards available to medical device companies in any state. For Texas-based companies (or those willing to relocate) developing cancer-related diagnostic, therapeutic, or enabling devices, CPRIT should be a primary funding target alongside federal SBIR/STTR and venture capital.
Not sure which programs may fit your medical device company? Our free screening report checks your business against 150+ verified programs — grants, tax credits, loans, and incentives — and shows you which ones may match. Start your free screening →